Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771568 | 0.94 | MAP4K4 (0.42) | HRH4HCRTR1HCRTR2HTR2CKDR | |
| SCHEMBL5770583 | 0.92 | HCRTR1 (0.42) | HRH4HCRTR1HCRTR2HTR2C | |
| SCHEMBL5772442 | 0.90 | HRH4 (0.43) | HRH4HCRTR1HCRTR2HTR2CKDR | |
| SCHEMBL5771577 | 0.88 | HRH4 (0.41) | HRH4HTR2CKDRTNKSPARP1 | |
| SCHEMBL5773249 | 0.86 | HCRTR1 (0.42) | HCRTR1HCRTR2HTR2C | |
| SCHEMBL5795447 | 0.85 | PIM1 (0.41) | HRH4HTR2CKDRTNKS | |
| SCHEMBL5873073 | 0.82 | PIM1 (0.40) | HCRTR1HCRTR2KDRTNKSTLR8 | |
| SCHEMBL5873005 | 0.82 | KCNH2 (0.44) | HRH4HCRTR1HCRTR2HTR2CTNKS | |
| SCHEMBL5768252 | 0.79 | HCRTR1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL5872946 | 0.77 | HRH4 (0.40) | HRH4HCRTR1HCRTR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664040-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| WO-2005026162-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | HRH4 4233/4885HCRTR1 4881/4885HCRTR2 4876/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | HRH4 4233/4885HCRTR1 4881/4885HCRTR2 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.